In addition, two multicentre, open-label randomised phase III trials demonstrated that erlotinib delivered more significant PFS benefit and was better tolerated than standard chemotherapy in patients with advanced EGFR mutation-positive NSCLC [22]–[23]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.